Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Societal CDMO, Inc. (REPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Societal CDMO Reports Second Quarter 2023 Financial Results Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – August 14, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the second quarter and six months ended June 30, 2023. “The second quarter was a highly productive period. During the quarter, we co...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS"
05/10/2023 8-K Quarterly results
Docs: "Societal CDMO Reports First Quarter 2023 Financial Results Recorded Q1 Revenue of $21.5 Million Signed Multiple New Business Agreements with New and Existing Customers Granted FDA Approval for Manufacture of First Commercial Tablet Product Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – May 10, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarter ended March 31, 2023. “The company’s many achievements in 2022 placed Societal in an overall stronger financial position and paved the way for growth in 2023 and beyond. In the first quarter, we contin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS"
03/01/2023 8-K Quarterly results
Docs: "Societal CDMO Reports Fourth Quarter and Full Year 2022 Financial Results Recorded Q4 Revenue of $24.3 Million, a 9% Increase Compared to Prior Year Period Clinical Trial Materials Development Business Grew by 58% in 2022; Significantly Expanded and Diversified Customer Base Executed Multi-Step Strategy Resulting in Reduction of Debt and Strengthened Financial Position Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – March 1, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2022. “One year ago, the company outlin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS"
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "RECRO PHARMA, INC. AND SUBSIDIARIES Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 23,490 $ 23,760 Accounts receivable 13,746 9,033 Contract asset 7,314 7,330 Inventory 9,440 11,612 Prepaid expenses and other current assets 2,101 2,334 Total current assets 56,091 54,069 Property, plant and equipment, net 50,021 43,841 Operating lease asset 5,963 486 Intangible assets, net 5,993 700 Goodwill 39,568 4,319 Other assets 146 — Total assets $ 157,782 $ 103,415 Liabilities and shareholders’ equity Current liabilities: Accounts payable $ 1,916 $ 1,804 Current portion of debt — 1,474 Current portion of related party debt 2,039 — Current portion of operating lease liability 1,049 145 Accrued expenses and other current liabilities 7,856 4,380 Total current liabilities..."
05/06/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Secured Multiple New Contract Wins. During the third quarter, Recro secured multiple wins on Phase II modified release projects from new customers. All of the projects include analytical, formulation optimization and Clinical Trial Manufacturing work. • Continue to Execute and Expand Relationships with Existing Customers. Extension work from existing customers in the form of next step development proposals and additional batches continues to show healthy growth and is a strong sign of existing customers’ level of confidence in Recro’s technical and execution abilities. Approximately 90% of Recro’s development customers have proceeded to sign additional proposals for extension work and next phase development projects. • High Potency Oral Products Business on Track. Recro conti...",
"Investor presentation of Recro Pharma, Inc"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/04/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
Docs: "Recro Pharma Reports Third Quarter 2019 Financial Results"
08/08/2019 8-K Quarterly results
Docs: "Recro Pharma Reports Second Quarter 2019 Financial Results",
"Investor Presentation of Recro Pharma, Inc"
05/10/2019 8-K Quarterly results
Docs: "Recro Pharma Reports First Quarter 2019 Financial Results"
02/19/2019 8-K Quarterly results
11/07/2018 8-K Investor presentation, Quarterly results
Docs: "Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018",
"Investor Presentation of Recro Pharma, Inc"
08/07/2018 8-K Quarterly results
Docs: "Recro Pharma Reports Second Quarter 2018 Financial Results",
"Non-GAAP Reconciliation Slide"
05/09/2018 8-K Quarterly results
Docs: "Recro Pharma Reports First Quarter 2018 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registr...",
"Recro Pharma Reports Third Quarter 2017 Financial Results"
08/10/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Recro Pharma Reports Second Quarter 2017 Financial Results"
05/11/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
05/12/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy